Inside the research

TransMedics Group, Inc.

TMDX Research profile · latest available data

Price overview

$85.29

▲ +1.39 (+1.7%)

52w hi$150.42
52w lo$62.04
Vol696.70K
As of25 Sep 2026

The Verdict

Hold

Our score -0.19

Short-0.21
Medium-0.12
Long-0.28

computed 2026-09-27

Key fundamentals

TransMedics Group, Inc.

Healthcare · Medical Devices

Market cap$2.96B
Enterprise value$3.35B
Trailing P/E22.10x
Forward P/E37.34x
EV / EBITDA28.99x
P / S (ttm)4.41x
Profit margin22.7%
Return on equity36.3%
Revenue growth+20.7%
Earnings growth-55.8%
Debt / equity167.50

Layer Breakdown

LayerRawContribution
Fundamental+0.05
Sector+0.08
Technical-0.17
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

United States · www.transmedics.com

Risk Metrics

Beta vs SPX1.17
Corr SPX0.30
Annual vol63.7%
Annual ret-12.0%
Sharpe-0.19
Max DD-64.4%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-08-04Earnings Release, Exhibitsread
2026-05-21Shareholder Vote, Exhibitsread
2026-05-05Earnings Release, Exhibitsread
2026-02-27Earnings Release, Exhibitsread
2026-02-24Earnings Release, Exhibitsread
2026-02-04Officer / Director Changeread
2026-01-12Material Agreement, Other Material Event…read
2025-10-29Earnings Release, Exhibitsread
2025-10-06Acquisition / Dispositionread
2025-07-30Earnings Release, Exhibitsread
2025-05-23Shareholder Voteread
2025-05-08Earnings Release, Exhibitsread

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders7
Top-5 share100.0%
HHI5,339 (concentrated)

Top Holders

HolderValueShares
Citadel Advisors$94.13M1.42M
Millennium Management$17.47M263.01K
State Street Corp$13.00M11.94M
Fidelity / FMR LLC$6.03M5.58M
AQR Capital Management$1.86M27.95K
T. Rowe Price Group$3.06K46.03K
Capital Research / Capital World$1.08K1.00K

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-0410-Qview
2026-08-048-Kview
2026-07-144view
2026-07-144view
2026-07-144view
2026-06-174view
2026-05-224view
2026-05-224view
2026-05-224view
2026-05-224view
2026-05-224view
2026-05-224view
2026-05-224view
2026-05-218-Kview
2026-05-214view

The Long Run

FY 2019–2025 · 7 years

LineLatestCAGRTrend
Revenue$605.49M+143.4%
Gross profit$262.08M+156.3%
Operating income$108.58M+189.6%
Net income$190.29M—
Cash from ops$48.80M+0.0%

Indices

S&P SmallCap 600

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$83.50$85.69$81.80$85.29696.70K
Sep 24$86.09$86.09$82.53$83.90623.70K
Sep 23$88.22$89.19$85.07$87.00615.60K
Sep 22$88.15$89.80$86.50$88.07750.70K
Sep 21$87.35$89.53$86.75$87.29590.80K

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →